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10, with 10 being death). For most patients, MS will progress from an episodic
disorder (relapsing-remitting MS) to a more progressive state (secondary progressive
MS). We conducted a systematic review of the literature to determine how health
related quality of life, as measured by health utilities, changes with the increasing
neurological disability associated with different stages of MS. METHODS: Employing
pre-deﬁ ned search terms and inclusion/exclusion criteria, systematic searches 
were conducted in MEDLINE, EMBASE, PsycINFO, Health Economic Evaluation 
Database (HEED), NHS Economic Evaluations Database (NHS/EED), and the UK 
National Institute for Health and Clinical Excellence (NICE) website. All databases
were searched from 1 January 1993 to 5 August 2008. Data extraction was validated 
by an independent reviewer. RESULTS: We identiﬁ ed 16 studies reporting health utili-
ties associated with health states of MS. EQ-5D was the most common preference
elicitation instrument. Health utilities ranged from 0.80 to 0.89 for patients with an
EDSS score of 1, from 0.49 to 0.71 for patients with an EDSS score of 3, from 0.39 
to 0.54 for patients with an EDSS score of 6.5, and from 0.19 to 0.08 for patients
with an EDSS score of 9 with some patients valuing their health states as worse than 
death. CONCLUSIONS: MS has a signiﬁ cant impact on quality of life. Utilities 
decrease signiﬁ cantly with increasing neurological disability. Without taking into 
consideration EDSS score, there appears to be no difference in health utilities between
RRMS and SPMS patients and the variation in health utilities appears to be mainly 
explained by the severity of the disability. Utilities also decreased signiﬁ cantly during 
relapse phases.
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OBJECTIVES: Central Nervous System (CNS) studies often incorporate the use of 
patient-reported outcomes (PROs) because of the nature of disorders being studied 
and their dependence on the subjective reports of study subjects1. To date, limited 
data has been published that sheds light on the types of instruments that are collected 
electronically (ePRO) in CNS trials. This research studied the breadth and depth of 
ePRO use through the analysis of a data set containing details of ePRO use in phase 
I-IV CNS drug trials. METHODS: A study of the characteristics of ePRO use in CNS
clinical drug trials was undertaken to understand the breath of CNS disorders areas
in which ePRO is being used as well as to understand how ePRO is being used within
these trials. A dataset of 91 clinical trials was analyzed by using ﬁ elds that describe
each protocol’s key elements including ePRO instrument, Phase, Assessment Fre-
quency, Disorder and Target Population. RESULTS: The analysis determined that 
Depression and sleep disorders respectively represented 33.3% and 34% of ePRO use 
for this dataset. Overall, ePRO was used in 12 different CNS disorders. ePRO was
most often used to collect primary efﬁ cacy data (24%), but other uses included second-
ary efﬁ cacy (22%) and safety (4.4%) data. The most common reporting frequency 
was for screening or study eligibility assessment (24%); this was followed closely by 
daily (19.8%) assessment. Of interest was that 79% of the time, a named instrument 
is used as opposed to a diary or symptom questionnaire (21%). CONCLUSIONS:
This research shows that PROs are not only being collected electronically, but that
ePRO use within CNS clinical trials is both broad and deep. Limitations of this study 
include the clinical trials of this dataset which can not be necessarily generalized as 
representative of all CNS ePRO use.
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OBJECTIVES: To assess and describe the diagnostic and treatment pathways of move-
ment disorders responsive to BoNTA, Allergan Units and assess the types and number 
of health care professionals seen by patients before their movement disorder diagnosis 
was made and the length of time from onset of symptoms to diagnosis. METHODS:
Patients with movement disorders completed a 19-question survey developed by the
Canadian Movement Disorders Survey Group. Questions included patient demo-
graphics, length of time from onset of symptoms, number and types of physicians 
seen, other diagnoses made, number of patients treated with BoNTA and distance 
traveled. RESULTS: In this ﬁ nal analysis, 879 patients with movement disorders 
responsive to BoNTA were surveyed. Majority of the patients were female (72%), 
traveling an average of 69 km one-way. Most common movement disorder diagnoses 
were cervical dystonia (42%), hemifacial spasm (20%), and blepharospasm (9%).
Common diagnoses made prior to the movement disorder diagnoses were nerve/muscle 
problem (33%), stress/psychological problem (39%), tremor (16%), ﬁ bromyalgia 
(14%), TMJ (10%), joint/tendon problem (15%) and spine (10%). The average 
number of physicians seen before the movement disorder diagnosis was 3.1. Amongst
these were family physicians (78%), neurologists (71%), movement disorder special-
ists (32%), chiropractors (17%), eye care doctors (17%), physiotherapists (17%), and
neurosurgeons (10%). Most physicians who made the current movement disorder
diagnoses were neurologists (63%) and movement disorder specialists (33%). The
average time in years from onset of symptoms to movement disorder diagnosis were:
cervical dystonia 6.6, blepharospasm 4.7, hemifacial spasm 3.8, spasmodic dysphonia 
2.5, limb dystonia 8.2, Meige syndrome 2.8, generalized dystonia 1.6, oromandibular 
dystonia 2.1. 95% of patients were treated with BoNTA following their movement
disorder diagnosis. CONCLUSIONS: The number of physicians seen and length of 
time from onset to movement disorder diagnoses are considerable. Increased aware-
ness of movement disorders at the primary care level may improve these rates.
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OBJECTIVES: Brain abscess is a somewhat rare condition found more commonly in 
pediatric patients than young adults. While fatalities as a result of brain abscesses have 
decreased signiﬁ cantly in recent years, the possibility of the condition being fatal is 
very real. Early diagnosis and treatment are the keys to effectively resolving the issue. 
The purpose of this paper is to examine patient outcomes for those diagnosed with
brain abscess. METHODS: Data were taken from the National Inpatient Sample
(NIS). The data consist of pediatric patients diagnosed with brain abscesses (N  252) 
and a randomly selected control group (N  260). SAS Enterprise Guide, a statistical
software program, was used to analyze the data set and provide an overview of the
results. Methods used included one-way frequencies, statistical summaries, kernel
density estimations, and linear and logistic regression models. RESULTS: Contrary to 
other sources, the age of pediatric patients in the sample seems to play a role in the
likelihood of developing brain abscesses. Factors such as age, gender, and race were 
shown by several different methods to be not signiﬁ cant in the diagnosis. The mortality 
rate was found to be ﬁ ve times higher in the treatment group than the control sug-
gesting that while this condition may be declining with respect to deaths, the rate is 
still signiﬁ cantly higher than a random control group from the NIS database. CON-
CLUSIONS: While the mortality rate for brain abscesses is low, current procedures 
can still be improved to lower the rate further. New techniques of diagnosing brain
abscesses can also be developed with the research found in the NIS. Further studies 
should be performed in order to ﬁ nd more relationships. Finding the connection 
between these connections may lead to better preventive measures and improved
treatments for brain abscesses.
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OBJECTIVES: To assess factors associated with health-related quality of life (HRQoL) 
in MS patients after three natalizumab infusions. METHODS: MS patients, newly 
enrolled in the manufacturer’s restricted drug distribution program and participating
in a longitudinal study of their experiences with natalizumab, complete assessments
prior to treatment initiation and after the 3rd, 6th and 12th infusion. HRQoL was 
assessed with the SF-12v2 where higher physical and mental component summary 
(PCS and MCS) scores indicated improvement in HRQoL. Univariate, followed by 
multivariate, linear regression was used to identify factors associated with HRQoL
after three natalizumab infusions. The factors used in this analysis include age, clinical 
characteristics (disease duration, number of prior MS treatments) and baseline (BL) 
disease severity measures (disease step (DS), functional status, fatigue score, cognitive 
functioning (CF) score). RESULTS: At the time of this analysis 504 patients had 
completed BL and 3rd assessments. Mean age was 46.08 o 10.93, 78% of patients 
were female, and mean disease duration was 9.64 o 8.33 years. PCS and MCS scores
improved signiﬁ cantly from baseline (PCS: 34.03 versus 36.02; p  0.001) and MCS:
43.17 versus 47.22; p  0.001). Multivariate analysis indicated that higher BL PCS
scores (p  0.001), lower BL DS scores (p  0.001) and younger age (p  0.002) were 
associated with improvement in PCS scores after three natalizumab infusions. Simi-
larly, higher BL MCS (p  0.001) and BL CF scores (p  0.001) were associated with 
improvement in MCS scores after the 3rd infusion. CONCLUSIONS: Factors associ-
ated with improvement in PCS scores after the 3rd infusion were younger age, higher 
BL PCS scores, and lower BL DS scores (better ambulation) while those associated
with improvements in MCS scores were higher BL MCS scores and higher BL CF 
scores. These results suggest that initiating natalizumab in younger patients having 
lower disability and better baseline HRQoL results in greater improvements in 
HRQoL after three natalizumab infusions.
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OBJECTIVES: Parkinson’s disease (PD) is a progressive neurodegenerative disorder 
that affects 1 million people in the United States. Several available treatments are 
effective in controlling its symptoms; however, relatively little research has examined
patient- and physician-reported PD treatment satisfaction/ease-of-use (SEU) ratings.
These post-hoc analyses examined whether improvement in PD symptoms and dis-
abilities predicted subsequent ratings of SEU with rasagiline, a selective irreversible 
monoamine oxidase type-B inhibitor. METHODS: The LEGATO trial was an open-
label study of 0.5 mg and 1.0 mg once daily rasagiline in PD patients at 38 commu-
nity-based centers in the United States. Baseline treatment determined patients’
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stratiﬁ cation to mono- or adjunct therapy. Outcome variables were patient- and physi-
cian-reported treatment SEU ratings at weeks 4 and 12. Predictors included change
from baseline in the bradykinesia subscale of the Uniﬁ ed Parkinson’s Disease Rating
Scale, change from baseline in patient- and physician-reported Activities of Daily 
Living (ADL), and patient- and physician-reported Clinical Global Impression (CGI).
Data were analyzed using linear regression. RESULTS: SEU ratings with rasagiline 
were positive at all visits. Complete data were available for 109 monotherapy and 
131 adjunct therapy patients at week 12. Patient- and physician-reported CGI 
were positively related to SEU ratings reported by the same individual at the same 
visit (p  0.05); patient-reported CGI was positively related to physician-reported SEU
ratings at week 4 (p  0.05). Bradykinesia improvement from baseline predicted physi-
cian-reported SEU ratings at week 4 for monotherapy (p  0.01). Patient-reported
ADL improvement from baseline predicted patient-reported SEU ratings at week 12 
for adjunct therapy (p  0.01). CONCLUSIONS: Patient- and physician-reported CGI 
were consistently related to patient- and physician-reported SEU ratings with rasagi-
line. Furthermore, improvement in bradykinesia symptoms and patient-reported ADL
predicted subsequent ratings of treatment SEU in some cases. Additional research on 
patient- and physician-reported treatment SEU scales in PD populations is needed to 
reﬁ ne this important endpoint.
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University of Sao Paulo, Sao Paulo, SP, Brazil
OBJECTIVES: Multiple Sclerosis (MS) is an immunomediated, highly disabling
disease affecting young adults. The demographic characteristics, disease modifying 
therapies and health resources utilization by patients followed at a MS reference center
in Sao Paulo, Brazil are presented. METHODS: Patient’s charts were reviewed from 
a retrospective cohort of 353 MS patients. Patients were selected by attendance to 
outpatient visits at Hospital das Clínicas, Faculty of Medicine – University of Sao 
Paulo from March to May 2008. RESULTS: From 353 patients, 74% were female
and 86% were white-Caucasians. A positive family history was identiﬁ ed in ﬁ ve
patients. Sixty-eight percent had relapsing-remitting MS, 13% secondary progressive
MS and 10% primary progressive MS. Half of the patients had MS diagnosis for less 
than 5 years. At the last interview, 226 patients (64%) were on immunomodulatory
agents. From these, 59 patients were using glatiramer acetate and 167 were using 
beta-interferons. The immunomodulatory drug was changed in 11 patients. Sixty-one 
patients (17%) were on immunossupressants, with 31% using azathioprine. Average 
EDSS score at last visit was 4.2. Approximately 24% of patients had at least one 
relapse requiring treatment and 5% were hospitalized in the last 12 months. CON-
CLUSIONS: There are few data on epidemiology and health resource use published 
in Latin-American countries, while many countries like Brazil provide high-cost treat-
ments at public health system. In our study, the current approved MS therapies were
widely used. Therefore, the understanding of local patients’ characteristics and health 
resources use can provide data for an optimized, tailored disease management solu-
tions in these countries.
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OBJECTIVES: Examine the patient characteristics, treatment patterns and cost of care
among Parkinson’s Disease (PD) residents in a long term care (LTC) setting, speciﬁ -
cally, skilled nursing facilities (SNFs) in the US. PD is a progressive neurodegenerative
disorder that produces considerable morbidity. The prevalence and incidence of PD 
increase with age. PD affects more than 3% of individuals over 65 years old.
METHODS: Retrospective analysis of PD patients in SNFs from June 2004–2008.
Using a large provider database, 7885 PD patients were identiﬁ ed. Patient demograph-
ics, comorbidities, treatment patterns and costs were assessed using administrative and 
clinical databases at baseline and one year (1 year). RESULTS: A total of 4150 PD 
patients with baseline and 1 year data constituted the analysis cohort, mean age of 
82 years, 46% male and 57% admitted from an acute care hospital. At baseline, 43%
had fallen in the past 30 days, 94% reported bathing assistance; 24% and 38% were
bladder and bowel continent; 71% and 44% suffered short and long-term memory 
loss. Patients received speech, occupational and physical therapy for 68, 153 and 157
minutes per week. The average patient had 6 comorbid conditions: hypertension
(64%), depression (46%), dementia (43%) and diabetes (31%) were common. 83%
were diagnosed with PD before or at SNF admission. At baseline, 79% were PD 
medication-free; 49% remained PD medication-free over 1y. Patients averaged 11
medications. Concomitant medication use of analgesics, antihypertensives and antide-
pressants were the most common. Direct LTC monthly medical costs were $5355 and
$6097 at baseline and 1 year. CONCLUSIONS: PD patients have physical and cogni-
tive impairment, combined with debilitating comorbidities. Falls, incontinence, 
memory loss, hypertension, depression, dementia and diabetes complicate PD treat-
ment in LTC. Concomitant medication burden further complicates treatment. Ongoing
examination into treatment needs and barriers to PD medication use is needed to
alleviate PD burden in LTC.
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OBJECTIVES: Our study aims to identify socioeconomic factors related to insomnia
prescription patterns in US outpatient settings. METHODS: This project proposes a 
secondary data analysis using a national longitudinal database from 2004 National 
Ambulatory Medical Care Survey (NAMCS). Study subjects were derived from out-
patient visits in which at least one insomnia drug was prescribed. A series of weighted
chi-square statistics were performed to compare insomnia drug uses across various
physician and patient characteristics. All analyses used SAS statistical software and 
incorporated sample weights and standard errors correction. RESULTS: Among the 
910 million outpatient visits that took place in the US in 2004, an estimated 24.
98 million visits included at least one insomnia drug prescription. The majority of 
prescriptions were allocated to antidepressants (52.3%), which were more frequently 
prescribed than non-benzodiazepines (34.1%) and benzodiazepines (13.6%). Differ-
ences in drug pricing may explain these ﬁ ndings: the average wholesale price (AWP) 
for antidepressants is lower ($0.31) than non-benzodiazepine hypnotics ($2.52). 
Patient comparisons by insurance type revealed that Medicaid patients were less likely 
to receive the relatively expensive non-benzodiazepines (27.55%) than Medicare 
(32.53%), self-pay (33.39%), and private insurance (35.03%) patients. Prescribing
patterns were signiﬁ cantly inﬂ uenced by physician specialty (P  0.0001), with general/
family physicians contributing the greatest frequency of insomnia prescriptions 
(36.1%). Females received signiﬁ cantly more insomnia prescriptions than males (16.4
mil. vs. 8.58 mil.; P  0.0001) and Black/Hispanics received signiﬁ cantly fewer
insomnia prescriptions than did white patients (10.78% vs. 87.13%, P  0.0001). 
CONCLUSIONS: Our ﬁ ndings indicate signiﬁ cant socioeconomic disparities in the 
use of insomnia prescriptions. While drug pricing might account for some of our 
results, marketing—particularly the sociodemographic and physician characteristics
toward which such efforts are targeted—provides another strong explanation for
prescription pattern disparities. Further evaluation of current practice guidelines and
development of more manageable regulations might ensure greater consistency in 
treatment patterns.
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TREATMENTS OF NEUROLOGICAL DISORDERS
Tesar T, Foltan V, Binder R
Comenius University, Bratislava, Slovak Republic
OBJECTIVES: To analyse the utilisation of drugs for treatment of neurological disor-
der (ATC group: N01–N07) within Slovakia between 1999 and 2007 and to asses the
economic consequences of the medications. METHODS: For 1999–2007, the data
about consumption of drugs for treatment of neurological disorder were collected 
following ATC/DDD methodology. Data of wholesalers, who are legally obliged
provide this information to the Slovak Institute for Drug Control, was used for
the analysis. The results were expressed in the numbers of the packages, ﬁ nance units 
(€) and deﬁ ned daily doses per 1000 inhabitants per day (DID). RESULTS: The col-
lected data showed a signiﬁ cant increases in consumption of drugs for treatment of 
neurological disorder from 1999 to 2007 in term of DID (in 1999 (108.92), in 2003
(119.46) and in 2007 (142.57). A large increase in consumption of psychoanaleptics
(in 1999 (16.00), in 2003 (33.22) and in 2007 (44.84) and a stable consumption of 
psycholeptics in 1999 (40.88), in 2003 (38.33) and in 2007 (41.34) in term of DID 
can be seen from this analysis. We can see a slight increase in consumption of drugs 
in term of DID within the group of antiepileptics (in 1999 (4.60), in 2003 (5.25) and
in 2007 (6.86) and anti-parkinson drugs (in 1999 (3.19), in 2003 (3.81) and in 2007 
(3.92). Financial expenditures for psychoanaleptics (in 1999 (€16,613,000), in 2003 
(€40,572,000) and in 2007 (€30,382,000), for psycholeptics (in 1999 (€10,504,000), 
in 2003 (€24,603,000) and in 2007 (€36,502,000) can be seen from this study. CON-
CLUSIONS: Inseparable components of the Slovak drug policy must be viewed real-
istically with regard to the consumption of drugs for neurological disorder. Adherence 
to principles of neurological treatment’s guidelines lead to fundamental short and long
term ﬁ nancial savings within health care systems.
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OBJECTIVES: Cholinesterase (ChE) inhibitors, including donepezil and rivastigmine,
are standard of care for mild to moderate cognitive impairment due to Alzheimer’s 
disease (AD). The current study investigates whether treatment with rivastigmine is
associated with less use of antipsychotics compared to treatment with donepezil. 
METHODS: A claims analysis was conducted from 01/2004 through 12/2006 using
the MedStat MarketScan database. Patients included had continuous insurance cover-
age, had at least 1 diagnosis of AD, and were newly initiated on either rivastigmine
or donepezil after the ﬁ rst AD claim. Patients using memantine or receiving antipsy-
chotics in the time interval of q180 days before and 14 days after the ﬁ rst rivastigmine 
or donepezil drug dispensing were excluded. Both Kaplan-Meier and multivariate Cox 
